ProCE Banner Activity

Latest Insights on Ki-67 Use in HR-Positive/HER2-Negative Early Breast Cancer

Clinical Thought
Laura M. Spring, MD, a breast cancer medical oncologist, and Sunil Badve, MD, FRCPath, a surgical pathologist, provide insights into the role and utility of Ki-67 testing in HR-positive/HER2-negative early breast cancer in this expert commentary.

Released: September 26, 2022

Expiration: September 25, 2023

No longer available for credit.



Sunil Badve

Sunil Badve, MD, FRCPath

Laura M. Spring

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by a partnership between the American Society for Clinical Pathology and Clinical Care Options, LLC.
ProCE Banner


This activity is supported by an educational grant from